Regeneron and Sanofi's Dupixent (dupilumab) Receives FDA's Approval for Chronic Rhinosinusitis with Nasal Polyposis
Shots:
- The approval is based on two SINUS-24 & SINUS-52 studies results assessing Dupixent (300mg- q2w) + mometasone furoate nasal spray (MFNS) vs PBO + MFNS in patients with CRSwNP with uncontrolled disease
- The SINUS-24 & 52 studies results: nasal congestion/obstruction improvement (57% & 51% vs 19% & 15%); reduction in nasal polyps score (33% & 27% vs 7% & 4%); improvement in sinus opacification (42% & 27% vs 4% & 0%); improvement in loss of smell (52% & 45% vs 12% & 10%); 83% reduction in surgery; 74% reduction in systemic corticosteroids administration
- Dupixent (SC) is a mAb inhibiting the signals IL-4 & IL-13 available as pre-filled syringe- approved in EU- Japan & Australia for asthma and is under review in EU for CRSwNP & in Japan & EU for atopic dermatitis
Click here to read full press release/ article | Ref: Regeneron | Image: The Pike Company
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com